Fibroblast growth factor receptor 4: A putative key driver for the aggressive phenotype of hepatocellular carcinoma

Carcinogenesis

Volumn 35, Issue 10, 2014, Pages 2331-2338

  Gauglhofer, Christine ^a   Paur, Jakob ^a   Schrottmaier, Waltraud C ^a   Wingelhofer, Bettina ^a   Huber, Daniela ^a   Naegelen, Isabelle ^a   Pirker, Christine ^a   Mohr, Thomas ^a   Heinzle, Christine ^a   Holzmann, Klaus ^a   Marian, Brigitte ^a   Schulte Hermann, Rolf ^a   Berger, Walter ^a   Krupitza, Georg ^b   Grusch, Michael ^a   Grasl Kraupp, Bettina ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR RECEPTOR 4; SMALL INTERFERING RNA; TRANSCRIPTOME; FGFR4 PROTEIN, HUMAN;

ADENOVIRUS INFECTION; ANCHORAGE INDEPENDENT GROWTH; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARCINOGENESIS; CELL ADHESION; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; CONTROLLED STUDY; EXTRACELLULAR MATRIX; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HEPG2 CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; ANIMAL; CELL PROLIFERATION; DRUG SCREENING; GENE SILENCING; GENETICS; LIVER TUMOR; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL ADHESION; CELL LINE, TUMOR; CELL PROLIFERATION; GENE KNOCKDOWN TECHNIQUES; HUMANS; LIVER NEOPLASMS; MICE; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 4; SIGNAL TRANSDUCTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84920971419     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgu151     Document Type: Article

References (36)

1. Forner, A. et al. (2012) Hepatocellular carcinoma. Lancet, 379, 1245-1255.
2. Ferenci, P. et al. (2010) Hepatocellular carcinoma (HCC): a global perspective. World Gastroenterology Organization. J. Clin. Gastroenterol., 44, 239-245.
3. Marquardt, J.U. et al. (2012) Molecular diagnosis and therapy of hepatocellular carcinoma (HCC): an emerging field for advanced technologies. J. Hepatol., 56, 267-275.
4. Calvisi, D.F. et al. (2012) Deregulation of signalling pathways in prognostic subtypes of hepatocellular carcinoma: novel insights from interspecies comparison. Biochim. Biophys. Acta, 1826, 215-237.
5. Gauglhofer, C. et al. (2011) Up-regulation of the fibroblast growth factor 8 subfamily in human hepatocellular carcinoma for cell survival and neoangiogenesis. Hepatology, 53, 854-864.
6. Ho, H.K. et al. (2009) Fibroblast growth factor receptor 4 regulates proliferation, anti-apoptosis and alpha-fetoprotein secretion during hepatocellular carcinoma progression and represents a potential target for therapeutic intervention. J. Hepatol., 50, 118-127.
7. Wang, L. et al. (2012) A novel monoclonal antibody to fibroblast growth factor 2 effectively inhibits growth of hepatocellular carcinoma xenografts. Mol. Cancer Ther., 11, 864-872.
8. Turner, N. et al. (2010) Fibroblast growth factor signalling: from development to cancer. Nat. Rev. Cancer, 10, 116-129.
9. Heinzle, C. et al. (2011) Targeting fibroblast-growth-factor-receptordependent signaling for cancer therapy. Expert Opin. Ther. Targets, 15, 829-846.
10. Cheng, A.L. et al. (2011) Targeting fibroblast growth factor receptor signaling in hepatocellular carcinoma. Oncology, 81, 372-380.
11. Wu, X. et al. (2012) Understanding the structure-function relationship between FGF19 and its mitogenic and metabolic activities. Adv. Exp. Med. Biol., 728, 195-213.
12. Heinzle, C. et al. (2014) Is fibroblast growth factor receptor 4 a suitable target of cancer therapy? Curr. Pharm. Des., 20, 2881-2898.
13. Nicholes, K. et al. (2002) A mouse model of hepatocellular carcinoma: ectopic expression of fibroblast growth factor 19 in skeletal muscle of transgenic mice. Am. J. Pathol., 160, 2295-2307.
14. Desnoyers, L.R. et al. (2008) Targeting FGF19 inhibits tumor growth in colon cancer xenograft and FGF19 transgenic hepatocellular carcinoma models. Oncogene, 27, 85-97.
15. Sawey, E.T. et al. (2011) Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by Oncogenomic screening. Cancer Cell, 19, 347-358.
16. French, D.M. et al. (2012) Targeting FGFR4 inhibits hepatocellular carcinoma in preclinical mouse models. PLoS One, 7, e36713.
17. Francavilla, C. et al. (2013) Functional proteomics defines the molecular switch underlying FGF receptor trafficking and cellular outputs. Mol. Cell, 51, 707-722.
18. Sagmeister, S. et al. (2008) New cellular tools reveal complex epithelialmesenchymal interactions in hepatocarcinogenesis. Br. J. Cancer, 99, 151-159.
19. Harding, T.C. et al. (2013) Blockade of nonhormonal fibroblast growth factors by FP-1039 inhibits growth of multiple types of cancer. Sci. Transl. Med., 5, 178ra39.
20. Kerjaschki, D. et al. (2011) Lipoxygenase mediates invasion of intrametastatic lymphatic vessels and propagates lymph node metastasis of human mammary carcinoma xenografts in mouse. J. Clin. Invest., 121, 2000-2012.
21. Schoppmann, S.F. et al. (2004) Telomerase-immortalized lymphatic and blood vessel endothelial cells are functionally stable and retain their lineage specificity. Microcirculation, 11, 261-269.
22. Fischer, H. et al. (2008) Fibroblast growth factor receptor-mediated signals contribute to the malignant phenotype of non-small cell lung cancer cells: therapeutic implications and synergism with epidermal growth factor receptor inhibition. Mol. Cancer Ther., 7, 3408-3419.
23. Ezzat, S. et al. (2001) A soluble dominant negative fibroblast growth factor receptor 4 isoform in human MCF-7 breast cancer cells. Biochem. Biophys. Res. Commun., 287, 60-65.
24. Losert, A. et al. (2006) Monitoring viral decontamination procedures with green fluorescent protein-expressing adenovirus. Anal. Biochem., 355, 310-312.
25. Subramanian, A. et al. (2005) Gene set enrichment analysis: a knowledgebased approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA, 102, 15545-15550.
26. Olsen, S.K. et al. (2004) Insights into the molecular basis for fibroblast growth factor receptor autoinhibition and ligand-binding promiscuity. Proc. Natl Acad. Sci. USA, 101, 935-940.
27. Chen, Q. et al. (2011) Soluble FGFR4 extracellular domain inhibits FGF19-induced activation of FGFR4 signaling and prevents nonalcoholic fatty liver disease. Biochem. Biophys. Res. Commun., 409, 651-656.
28. Cavallaro, U. et al. (2001) N-CAM modulates tumour-cell adhesion to matrix by inducing FGF-receptor signalling. Nat. Cell Biol., 3, 650-657.
29. Ezzat, S. et al. (2004) Pituitary tumor-derived fibroblast growth factor receptor 4 isoform disrupts neural cell-adhesion molecule/N-cadherin signaling to diminish cell adhesiveness: a mechanism underlying pituitary neoplasia. Mol. Endocrinol., 18, 2543-2552.
30. Christensen, C. et al. (2011) Neural cell adhesion molecule differentially interacts with isoforms of the fibroblast growth factor receptor. Neuroreport, 22, 727-732.
31. Staatz, W.D. et al. (1991) Identification of a tetrapeptide recognition sequence for the alpha 2 beta 1 integrin in collagen. J. Biol. Chem., 266, 7363-7367.
32. Adams, J.C. et al. (2004) The thrombospondins. Int. J. Biochem. Cell Biol., 36, 961-968.
33. Streuli, C.H. (2009) Integrins and cell-fate determination. J. Cell Sci., 122, 171-177.
34. Aszodi, A. et al. (2003) Beta1 integrins regulate chondrocyte rotation, G1 progression, and cytokinesis. Genes Dev., 17, 2465-2479.
35. LaFlamme, S.E. et al. (2008) Integrins as regulators of the mitotic machinery. Curr. Opin. Cell Biol., 20, 576-582.
36. Colello, D. et al. (2012) Integrins regulate microtubule nucleating activity of centrosome through mitogen-activated protein kinase/extracellular signal-regulated kinase kinase/extracellular signal-regulated kinase (MEK/ERK) signaling. J. Biol. Chem., 287, 2520-2530.